Price Increases For Branded Drugs Slower Since Medicare Drug Card – AARP
Executive Summary
The prices pharmaceutical manufacturers charge wholesalers for brand name drugs have been increasing at a slower rate since the Medicare drug discount card became available, AARP concludes in an "Rx Watchdog Report" released April 12
You may also be interested in...
AARP Rx Watchdog Report
AARP's latest drug price study, issued Nov. 2, found prices rose 6.1% for nearly 200 of the most common brand name prescriptions during the 12 month period ending in June. The rate is slightly less than the 7.1% increase reported by AARP in 2004 (1"The Pink Sheet" April 18, 2005, p. 16). Products with the "sharpest" price increases over the first six months of 2005 included Sanofi-Aventis' Ambien 5 mg (14.4%) and Boehringer Ingelheim's Atrovent (18.6%). The Pharmaceutical Research & Manufacturers of America disputed the report, stating the Consumer Price Index price for prescription drugs increased only 3.4% for the same period...
AARP Rx Watchdog Report
AARP's latest drug price study, issued Nov. 2, found prices rose 6.1% for nearly 200 of the most common brand name prescriptions during the 12 month period ending in June. The rate is slightly less than the 7.1% increase reported by AARP in 2004 (1"The Pink Sheet" April 18, 2005, p. 16). Products with the "sharpest" price increases over the first six months of 2005 included Sanofi-Aventis' Ambien 5 mg (14.4%) and Boehringer Ingelheim's Atrovent (18.6%). The Pharmaceutical Research & Manufacturers of America disputed the report, stating the Consumer Price Index price for prescription drugs increased only 3.4% for the same period...
PhRMA Studies Contest AARP Drug Price “Watchdog Report”
Prescription drug prices rose only 0.9% in the first quarter of 2004, not 3.4% as AARP claims, a study of Bureau of Labor Statistics data commissioned by the Pharmaceutical Research & Manufacturers of America says